Acutaas Chemicals Limited has announced a shift in the status of its subsidiary, Acutaas Chemicals Electrolytes Private Limited (ACEPL). Following a private placement of 1,111 equity shares to A.R.Z. Pharma Ltd., the parent company’s stake in ACEPL has decreased from 100% to 90%. Despite this dilution, ACEPL remains a subsidiary under the control and management of Acutaas Chemicals, with the number of shares held by the parent company remaining unchanged.
Strategic Investment in ACEPL
On May 19, 2026, the Board of Directors of Acutaas Chemicals Electrolytes Private Limited (ACEPL) approved a preferential issuance of shares to A.R.Z. Pharma Ltd. The transaction involved the allotment of 1,111 equity shares at an issue price of Rs. 52,490 per share, which includes a premium of Rs. 52,480 per share.
Impact on Shareholding and Status
As a result of this capital infusion, Acutaas Chemicals Limited’s ownership in its subsidiary, ACEPL, has transitioned from a wholly owned subsidiary to a 90% owned subsidiary. While the ownership percentage has shifted, the company emphasized that this transaction does not impact the management control of ACEPL, which continues to fall under the oversight of Acutaas Chemicals Limited.
Payment Schedule
The issuance is structured on a partly paid-up basis. The initial 25%, amounting to Rs. 1,45,79,097.50, was collected upon application and allotment. The remaining 75%, totaling Rs. 4,37,37,292.50, is scheduled to be called up on or before May 2, 2027, within twelve months of the issuance date.
Source: BSE
